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Background: Optimising quality of life (QoL) remains the central tenet of care in patients 
with incurable cancer, however determinants of QoL are not clear. The aim of the present study 
was to examine which factors influence QoL in patients with incurable cancer. 
Methods: A multi-centre study of adult patients with advanced cancer was conducted in 
Ireland and the United Kingdom between 2011-2016. Data were collected from patients at 
study entry and included patient demographics, Performance Status (ECOG-PS), nutritional 
parameters [weight loss (%WL) and muscle parameters assessed using computed tomography 
images (skeletal muscle index (SMI) and skeletal muscle attenuation (MA)], inflammatory 
markers [modified Glasgow Prognostic score (mGPS)] and QoL data (EORTC QLQ-30). The 
relationship between clinical, nutritional and inflammatory parameters with QoL was assessed 
using the Spearman-rank correlation coefficient and multivariate binary logistic regression. 
Components of the EORTC-QLQ (physical function, fatigue and appetite loss) and the 
summary QoL score were mean-dichotomised for the logistic regression analyses. 
Results: Data were available on 1027 patients (51% male, median age 66 years). 
Gastrointestinal cancer was most prevalent (40%), followed by lung (26%) and breast (9%). 
Distant metastatic disease was present in 87% of patients had metastatic disease. %WL, 
ECOG-PS and mGPS were significantly correlated with deteriorating QoL functional and 
symptom scales (all p<0.001). On multivariate regression analysis, >10% WL (OR 2.69 [95% 
CI:1.63-4.42]), ECOG-PS 3-4 (OR 14.33 [95% CI:6.76- 30.37]) and mGPS 2 (OR 1.58 [95% 
CI:1.09- 2.29]) were independently associated with poorer summary QoL score. These 
parameters were also independently associated with poorer physical function, fatigue and 
appetite loss (all p<0.05). Low MA was independently associated with poorer physical 
functioning (OR 1.67 [95% CI:1.09-2.56]), but muscle parameters were not independently 
associated with fatigue, appetite loss or QoL summary score. 
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Conclusions: These findings indicate that QoL is determined (at least in part) by WL, ECOG-
PS and the systemic inflammatory response in patients with advanced cancer. Identifying early 
predictors of poor QoL may allow the identification of patients who may benefit from early 
referral to palliative and supportive care, which has been shown to improve QoL.  
 
INTRODUCTION 
The European Society of Medical Oncology (ESMO)1 advocate integrating supportive 
and palliative patient centred care into overall anti-cancer treatment at all stages of the disease. 
ESMO acknowledges that oncology patients’ needs are not being adequately met and that 
oncology care should encompass patient-centred supportive and palliative care from initial 
diagnosis to throughout the entire trajectory of the disease. Importantly, cancer care should not 
only aim to deliver the best quality anticancer treatment, but cancer care should now also 
consider the impact of a cancer diagnosis and its treatment on each patient’s life1. 
In patients who have an incurable cancer, the fundamental aim of treatment is to 
optimise quality of life (QoL). If this can be attained in unison with prolonged survival then 
this is clearly desirable, however if prolonged survival comes at the expense of impaired QoL 
then this may not be in the best interests of patients. Importantly, QoL is increasingly being 
recognised as an important prognostic indicator, and QoL has been shown to be associated with 
reduced survival in a variety of cancer sites, even after adjusting for known prognostic clinical 
variables2-5. 
 The now, almost routine adoption of patient reported outcome measures (PROMs) of 
QoL into cancer clinical trials, has enhanced our understanding of this area.6 The European 
Organisation for the Research and Treatment of Cancer (EORTC) have now developed over 60 
QoL modules, including the universal EORTC Quality of Life Questionnaire C-30 (EORTC 
QLQ-C30)7. Using this, it has been shown that both physical function (performance score) and 
measures of the systemic inflammatory response (modified Glasgow Prognostic Score 
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[mGPS]) have a differential association with QoL.8,9 In a large cohort of 2,520 patients with 
advanced cancer, increasing mGPS and deteriorating performance status (ECOG) were 
associated with deterioration in quality-of-life parameters such as global health, role, physical 
and social functioning, and fatigue, pain, appetite symptoms (P < .001). The association with 
Increasing systemic inflammation and poorer quality-of-life parameters was independent of 
PS8. It has also been reported that other aspects including weight loss, body mass index and 
loss of muscle (sarcopenia) influence QoL in patients with cancer.10-12  
It has been argued that the host-tumour interaction and the resulting systemic 
inflammatory response is key in the genesis of how symptoms/quality of life are influenced in 
patients with cancer. Indeed work to date has supported this hypothesis demonstrating that the 
magnitude of the systemic inflammatory response influences the magnitude of symptoms in 
patients with cancer.8 Based on this, markers of the systemic inflammatory response are now 
advocated as key assessment criteria for staging nutritional status13 and as stratification factors 
in randomised clinical trials.14  In the same way that the tumour is staged, it has been argued 
that the host should be staged, as inflammatory status is likely to influence treatment outcomes 
and magnitude of symptoms.15 
However, a comparison of all factors known to influence QoL has yet to be done. 
Elucidation of those factors, which adversely influence QoL, may allow the identification of 
patients who may benefit from early referral to palliative and supportive care, which has been 
shown to improve QoL.16,17 Therefore, the aim of the present study was to examine the 
relationship between clinical, nutritional, inflammatory factors, and QoL, in patients with 








Data were collected across 18 sites in Ireland and Scotland (cancer centres, hospitals, 
and specialist palliative care units) over a period of 5 years (2011-2016). Patients were over 18 
years of age and had a diagnosis of incurable cancer. Incurable cancer was defined as 
metastatic disease or locally advanced disease being treated with palliative intent. Both 
inpatients and outpatients were recruited and a convenience sampling approach was adopted. 
Willing participants provided written informed consent. Exclusion criteria included patients 
that were under the age of 18 years of age and those that were unwilling or unable to 
participate due to cognitive impairment. Ethical approval was given for the data collection at 
all sites and was conducted according to good clinical practice and applicable laws.  
Procedure and Assessment 
Demographic data and clinical data were recorded and this included primary tumour 
site, stage and extent of metastatic disease (if present). The EORTC QLQ-C30 (version 3.0) 
was used to assess QoL.3 This 30-item cancer specific questionnaire includes five functional 
scales (physical, emotional, cognitive, social and role), three symptom scales (fatigue, pain, 
nausea/vomiting), a global health/QoL scale and six single items (dyspnoea, insomnia, appetite 
loss, constipation, diarrhoea and financial impact of disease). The 28 items measuring 
functional and symptom scales have a numeric scale: 1 (not at all), 2 (a little), 3 (quite a bit) 
and 4 (very much). The 2 items concerning global QoL have a scale of 1 (very poor) to 7 
(excellent). The raw scores were linearly transformed to give standard scores in the range of 0-
100 for each of the scales and single items as described by the EORTC18. Higher scores for the 
functional or global QoL scale represent a high level of functioning or QoL, whereas higher 
scores on the symptom scales represent worse symptomatology. The summary score of the 
EORTC QLQ-C30, which is comprised from the mean of 13 of the 15 QLQ-C30 scales (global 
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QoL scale and financial impact scale are not included), was used to assess overall summary 
QoL. with a maximum score of 100.19 The summary score was only calculated if all of the 
required 13 scale scores were available and the scoring of the QLQ-C30 summary score was 
calculated as follows:  QLQ-C30 Summary Score=(Physical Functioning+ Role Functioning+ 
Social Functioning+ Emotional Functioning+ Cognitive Functioning+ 100-Fatigue+ 100-Pain+ 
100-Nausea_Vomiting+ 100-Dyspnoea+ 100-Sleeping Disturbances+ 100-Appetite Loss+ 100-
Constipation+ 100-Diarrhoea)/13.19 
Nutritional parameters were also assessed. Patient’s weight, height and body mass 
index (BMI) (weight (kg)/height [m2]) were recorded. Patients were categorised according to 
their BMI as underweight (<20 kg/m2), normal weight (20-24.9 kg/m2), overweight (≥25-29.9 
kg/m2) or obese (≥30 kg/m2). Weight loss (WL) in the preceding 3 months was reported by 
patients, and when possible verified from patients’ medical records. 
C-reactive protein (mg/L)(CRP) and albumin (g/L) were used as markers of the 
systemic inflammatory response and were drawn by a venous blood sample at time of consent.  
Using both CRP and albumin, a modified Glasgow prognostic score (mGPS) was calculated 
accordingly.20 Patients who had both elevated CRP (>10 mg/L) and hypoalbuminemia (<35 
g/L) were assigned a score of 2. Patients with only an elevated CRP (>10 mg/L) and without 
hypoalbuminemia (albumin >35 g/L) were assigned a score of 1. Patients with neither of these 
abnormalities (i.e. CRP <10 mg/L and Albumin >35 g/L) were assigned a score of 0.21 The 
limit of detection of CRP was <5 mg/L. An increasing score is related to increasing systemic 
inflammation.20 
Performance status (PS) was assessed using the Eastern Oncology Cooperative Group 
(ECOG) score.22 Scores were assigned according to patient-reported daily physical function: 
0= fully active with no restrictions; 1= restricted in physically strenuous activity but 
ambulatory and able to carry out light work; 2= ambulatory and capable of all self-care but 
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unable to carry out any work activities; 3= capable of only limited self-care; 4= completely 
disabled and totally confined to bed or chair.  
 
Body composition assessment 
Abdominal Computerized Tomography (CT) images, taken as part of routine patient 
care within 12 weeks of QoL assessment, were used to assess body composition as previously 
described.23 The third lumbar vertebrae (L3) was chosen as the standard landmark and two 
consecutive transverse CT images where both transverse processes were clearly visible were 
analysed using OsiriX software version 4.1.1 (Pixmeo, Geneva, Switzerland) and ImageJ 
software version 1.47 (National Institutes of Health, MD, USA). Both imaging software 
packages have been shown to provide excellent agreement for body composition measures.24 
L3 was used as a standard landmark because it correlates best with whole body measures of 
muscle mass.25,26 Skeletal muscle area (cm2)(SMA) was manually outlined and segmentation 
of SMA was based on Hounsfield unit (HU) thresholds (-29 to +150 HU).27 SMA was 
normalized for stature to compute the skeletal muscle index (SMI)(cm2/m2). Mean muscle 
attenuation (MA) in HU was assessed in all patients with a contrast enhanced CT image and 
was reported for the entire SMA at L3. Gender and BMI specific cut points were used to define 
low SMI (sarcopenia) and low MA according to Martin et al.(2013).28 Measurements were 
performed by two individuals (RD and LD) and inter-rater reliability was assessed in a sample 
of 20 patient images using inter-class correlation coefficients (ICCC)(SMA ICCC=0.986, SMD 




Statistical analysis was conducted using SPSS (version 24.0, SPSS Inc., Chicago, IL, 
USA). Data are expressed as mean ± standard deviation (SD) or median [interquartile range, 
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IQR] where appropriate. Comparisons between groups of patients were assessed using Chi-
squared test for categorical variables and unpaired t tests and Mann-Whitney U tests to test for 
differences in continuous variables. Correlations were investigated using Spearman’s 
coefficient for non-parametric QoL data. The correlation coefficient (ρ) was used to determine 
the strength of the correlations. Cohen’s guidelines were employed when interpreting effect 
size and strength of correlations. These suggest that r=0.1-0.29 indicates a small effect size or 
correlation, r=0.3-0.49 indicates a medium effect size and r=0.5-1.0 indicates a strong effect 
size or correlation. Components of the EORTC-QLQ (physical function, fatigue and appetite 
loss) and the summary QoL score were mean-dichotomised for the logistic regression analyses 
assessing clinical, nutritional and inflammatory predictors of QoL. Patients with a score below 
the mean for physical function and QoL summary score, and above the mean for fatigue and 
appetite loss were given a score of 1, while those with a score above the mean for physical 
function and QoL summary score and below the mean for fatigue and appetite loss, were given 
a score of 0. Thus, odds ratios greater than 1.0 indicate a greater likelihood of worse QoL. 
Independent variables that had significance on univariate analysis were eligible for inclusion in 




Patient characteristics and demographics 
A total of 1027 patients with advanced cancer were recruited. Baseline demographic, 
clinical, nutritional and QoL characteristics are presented in Table 1. Patients were a median of 
4.6 months from diagnosis when they entered the study (IQR 3.0-13.0 months). In brief, 51% 
of patients were male and the median age was 66 (IQR 57-74) years. Gastrointestinal cancer 
was most common (40%) and metastatic disease was present in 87% of patients. In total, 830 
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patients (81%) were on active chemotherapy treatment (chemotherapy in the preceding 4 
weeks).  
 
Anthropometry and body composition 
Patients exhibited a wide variation in BMI (12.3-47.4 kg/m2). Half (51%) of all patients 
were overweight or obese (BMI ≥25 kg/m2), while only 13% had a BMI <20.0 kg/m2. Weight 
loss >5% in the preceding 3 months occurred in 277 (29%) patients, with 14% experiencing 
severe WL >10%. In terms of body composition, CT scans within 12 weeks of QoL assessment 
were available in 428 patients (contrast enhanced CT images for MA assessment available in 
413 patients). Overall, 192 (45%) patients were considered to have a low SMI (sarcopenia) and 
223 (54%) had low MA.  
Relationship between clinical, nutritional and inflammatory parameters with QoL 
The relationship between clinical, nutritional and inflammatory parameters to PROMs 
is displayed in Table 2.  
Within our cohort, female sex was significantly negatively correlated with poorer 
physical function (ρ=-.112, p=0.001), emotional function (ρ=-.071, p=0.024) and summary 
QoL score (ρ=-.080, p=0.012), and positively correlated with more nausea and vomiting 
(ρ=.123, p=0.001) and pain (ρ=0.068, p=0.030). Overall the strength of these correlations were 
small (ρ<0.3). Increasing age, negatively correlated with poorer physical (ρ=-.143, p=0.001) 
and role function (ρ=-.063, p=0.047) and positively with better emotional functioning 
(ρ=0.070, p=0.012). In terms of symptom scales, age was positively correlated with more 
fatigue (ρ=0.70, p=0.024), dyspnoea (ρ=0.089, p=0.005) and constipation (ρ=0.073, p=0.020). 
The presence of distant metastatic disease (vs. locoregional incurable disease) was not 
statistically significantly correlated with any EORTC functional or symptom scale.  
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Percentage WL, ECOG-PS and mGPS were negatively correlated with almost all 
EORTC functional scales (p<0.05). Importantly, medium to strong correlations (ρ>.30) were 
observed between ECOG-PS and mGPS with physical function (ρ=-.557, p<0.001 and ρ=-.312, 
p<0.001, respectively), and ECOG-PS with role function (ρ=-.494, p<0.001), social function 
(ρ=-.334, p<0.001), global health (ρ=-.410, p<0.001) and importantly summary QoL scores 
(ρ=-.500, p<0.001). The presence or absence of metastatic disease was not related to any of the 
PROMs. Interestingly, reduced EORTC reported physical functioning was more strongly 
correlated with low MA compared with low SMI (ρ=-.244 vs. ρ=-.164). Low SMI was not 
significantly associated with any other PROMS, whereas low MA was associated with role 
function (ρ=-.145, p=0.003), global health (ρ=-.175, p<0.001) and QoL summary score (ρ=-
.135, p=0.006). 
Table 3 depicts the relationship between the symptom components of the EORTC-QLQ 
and clinical, nutritional and inflammatory parameters. In line we what we observed in the 
PROMs functional scales, % WL, ECOG-PS, and mGPS were associated with increasing 
symptoms scores (p<0.05). Medium correlations (ρ>.30) were observed between ECOG-PS 
and fatigue (ρ=.476, p<0.001) and pain (ρ=.309, p<0.001), and as expected between % WL and 
anorexia (ρ=.311, p<0.001). Low MA was associated with more fatigue (ρ=.150, p=0.002) and 
dyspnoea (ρ=.150, p=0.002).  
In the multivariate logistic regression analyses, the QoL summary score was 
dichotomised by the mean (73.8). Odds ratios above 1.00 show an association with poorer 
overall QoL. On multivariate regression analysis, %WL (WL >5% OR:1.59 (95% CI: 1.01-
2.51) , p=0.048; WL >10% OR: 2.69 (95% CI: 1.63-4.42), p<0.001), ECOG-PS (PS 2: OR 
3.32 (95% CI: 2.34-4.70), p<0.001; PS 3-4: OR 14.33 (95% CI: 6.76-30.37), p<0.001), and 
mGPS (mGPS 1 OR: 2.05 (95% CI: 1.26-3.32), p=0.004; mGPS 2: OR 1.58 (95% CI: 1.09-
2.29), p=0.0016) were independently predictive of an overall QoL summary score below the 
mean (table 4).  
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In terms of physical function (<68.4), WL >10% (OR 1.92 (95% CI: 1.16-3.19), 
p=0.039), ECOG-PS (PS 2: OR 3.93 (95% CI: 2.77-5.58), p<0.001; PS 3-4: OR 18.07 (95% 
CI: 7.91-41.28), p<0.001), mGPS 2 (OR 2.01 (95% CI: 1.39-2.93), p<0.001) and female sex 
(OR: 1.56 (95% CI: 1.10-2.19), p=0.011), were independent predictors of poorer physical 
function on multivariate analysis (eTable 1).  
Examining predictors of fatigue (>42.3), on multivariate analysis WL >10% (OR 2.53 
(95% CI: 1.53-4.19), p<0.001), ECOG-PS (PS 2: OR 2.89 (95% CI: 2.06-4.07), p<0.001; PS 3-
4: OR 18.67 (95% CI: 7.79-44.7), p<0.001), and mGPS 2 (OR 1.57 (95% CI: 1.09-2.25), 
p<0.001) were independent predictors of more fatigue (eTable 2). 
On multivariate analysis, factors associated with more appetite loss (>27.3) were WL 
(WL >5%: OR 2.38 (95% CI: 1.51-3.76, p<0.001); WL >10%: OR 2.51 (95% CI: 1.58-3.99), 
p<0.001), ECOG-PS (PS 2: OR 1.86 (95% CI: 1.26-2.74), p=0.002; PS 3-4: OR 2.59 (95% CI: 
1.48-4.55), p=0.001) and mGPS (mGPS 1: OR 1.72 (95% CI: 1.02-2.91), p=0.043; mGPS 2: 
OR 1.64 (95% CI: 1.09-2.48), p=0.017)(eTable 3). 
On assessment of the relationship between muscle parameters and QoL (n=428), on 
univariate analysis low SMI was associated with poorer physical functioning (OR 1.72 (95% 
CI: 1.27-2.33), p<0.001) but not fatigue, appetite loss or summary QoL score (all p>0.05). 
However, on multivariate assessment (controlling for WL, ECOG-PS, mGPS, and low MA), 
low SMI was no longer associated with poorer physical functioning (OR 1.14 (95% CI: 0.74-
1.73), p=0.555). On univariate analysis, low MA was associated with poorer physical function 
(OR 2.31 (95% CI: 1.69-3.18), p<0.001), fatigue (OR 1.66 (95% CI: 1.22-2.25), p=0.001), 
appetite loss (OR 1.94 (95% CI: 1.33-2.84), p=0.001) and poorer summary QoL score (OR 
1.41 (95% CI: 1.03-1.92), p=0.032). However, after adjustment for % WL, ECOG-PS, mGPS, 
and low SMI, low MA was only independently associated with poorer physical functioning 




 Our study reports, for the first time, a comprehensive analysis of tumour and host 
factors and their effect on QoL in a large cohort of patients with incurable disease. Our finding 
indicate that QoL is determined (at least in part) by weight loss, performance status and the 
systemic inflammatory response in patients with advanced cancer.  Muscle mass and 
attenuation were significantly associated with some QoL domains on univariate analysis, 
however, on multivariate analysis, there was no significant independent association with 
fatigue, appetite loss or QoL summary score. Our findings suggest that interventions to 
mitigate the systemic inflammatory response and weight loss in patients with incurable cancer 
might have a positive impact on patients QoL.  
As expected, better ECOG-PS (scores 0-1) correlated with better physical, role, 
emotional and social functioning, global heath scores, and less fatigue, pain, anorexia and 
constipation (all p<0.001). Considering ECOG-PS is designed to determine a patient’s ability 
to carry out activities of daily living and general well-being, it is no surprise that ECOG-PS is 
associated with items of the EORTC QLQ-C30, and this relationship has been reported 
previously.8,29,30  
Our findings also demonstrate that the systemic inflammatory response, as evidenced 
by mGPS scores ≥1, is correlated with almost all EORTC functional and symptom scales. 
Furthermore, the mGPS was independently associated with physical functioning, fatigue, 
appetite loss and the QoL summary score. Our findings echo those previously reported in 
advanced cancer. Laird et al. reported that C-reactive protein was significantly associated with 
all of the functional components of the EORTC QLQ-C30, and a number of the symptoms 
including appetite loss, pain and fatigue.31   
In some instances, individual cytokines implicated in the pro-inflammatory response 
have been associated with clinical symptoms e.g. Interleukin-6 (IL-6) and CRP with 
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anorexia32, IL-1ra with fatigue32 and IL-6 with major depression.33,34 However, whether these 
cytokines exert their impact on symptoms in isolation or in combination is unclear. The reasons 
why systemic inflammation worsens QoL in patients with cancer has recently been reviewed35 
and evidence from a variety of preclinical and clinical studies suggest that the systemic 
inflammatory response has a direct role in the development of cancer associated symptom 
clusters including pain, fatigue, mood, anorexia and physical function.35 Importantly, the effect 
of systemic inflammation on QoL was independent of ECOG-PS, consistent with previous 
reports that showed the systemic inflammatory response (mGPS) to be associated with poorer 
QoL even in those with a good performance score.8 Research is warranted to determine if 
attenuating the systemic inflammatory response is capable of producing clinically relevant 
improvements in symptoms that may represent a new therapeutic approach to symptom 
management in patients with advanced cancer.  
We report herein that WL was associated with poorer QoL in almost all functional and 
symptom domains. In particular WL in excess of 10% in the preceding 3 months was 
independently associated with poorer physical function, fatigue, appetite loss and overall 
poorer QoL summary score. Weight loss is a frequent manifestation of malnutrition and is an 
important criterion for the diagnosis of cancer cachexia, a multifactorial syndrome 
characterised by a negative protein and energy balance driven by a variable combination of 
reduced food intake and abnormal metabolism36. In patients with cancer, cancer cachexia is 
often defined based on a single criterion, WL >5% over a period of 6 months. The adverse 
impact of WL on QoL has long been recognised in patients with cancer and WL has been 
associated with deterioration in patients’ performance status and psychosocial well-being.37-39 
In a recent systematic review examining the impact of WL and QoL, a negative relationship 
between %WL and QoL was reported in 23 of the 27 studies included in the analysis.11 
However, the mode by which WL exerts its influence on QoL is not fully understood but may 
relate to muscle atrophy associated with cachexia and weight loss leading to fatigue or reduced 
 14 
functional capacity.40 Importantly, interventions aimed at targeting nutritional status and 
attenuating WL have proven successful in improving aspects QoL in patients with cancer.41 In 
addition, novel cachexia treatments, such as Anamorelin, an oral ghrelin-receptor agonist with 
appetite enhancing and anabolic activity have shown a favourable clinical response in 
alleviating anorexia-cachexia symptoms.42,43 
When examining the impact of muscle parameters and QoL outcomes, low SMI was 
associated with poorer physical function and more insomnia, while low MA was correlated 
with poorer physical function, role function, global health and summary QoL and also with 
more fatigue and dyspnoea (all p<0.05). Low MA was independently associated with poorer 
EORTC reported physical functioning [HR 1.67 (95% CI: 1.09-2.56), p=0.018], whereas low 
SMI was not. This is consistent with previous reports that low MA is associated with physical 
functional impairments as evidenced by improvements in timed up and go, stair climb and 
walking.44. Inconsistent reports on this relationship between muscle parameters and QoL have 
been published in the literature.10,12,45,46 Parsons and colleagues reported no significant 
associations between low SMI and symptom burden or functional life domains assessed by the 
MD Anderson Symptom Inventory (MDASI) in a cohort of 104 patients with advanced 
cancer.45 However, in a study of 734 advanced lung cancer patients, low SMI was non-linearly 
associated with lower global QoL, physical function and role function, and associated with 
more symptoms (fatigue and pain), while low MA was associated with poor physical function 
and more dyspnoea.10 Our findings may be explained by the fact that low SMI, at one time 
point, is not reflective of a dynamic measure of loss and may be influenced by patient’s 
intrinsic level of muscularity. Within our study, the composition of WL, which influenced QoL 
was unknown, and perhaps losses of muscle over time may better reflect poor QoL. A growing 
body of evidence favours measures of muscle loss over time as prognostic of poor survival in 
patients with cancer compared with single point measurements. 47,48 
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The strengths of this study include the collection of numerous variables measured with 
appropriate methods simultaneously in a relatively large sample of patients with incurable 
cancer. In addition, using the QoL summary score to examine differences in QoL can avoid 
problems that may arise with multiple testing when otherwise making comparisons based on 
the 15 outcomes generated by the EORTC-QLQ questionnaire19. However, study limitations 
are also present. The aetiology of QoL is extremely complex given the web of determinants 
that influence it, and although we accounted for a number of clinical and nutritional 
parameters, the list of variables examined was not exhaustive. Given the convenient 
recruitment strategy, patients may have been at different time points of their disease trajectory 
when QoL was assessed (81% received chemotherapy in the previous 4 weeks), in addition 
patients may have received prior treatments, and this may have influenced QoL scores.’ 
 
Conclusion 
In summary, the findings herein provide evidence of the independent role of WL, 
ECOG-PS and systemic inflammation (mGPS) in predicting poorer physical functioning, more 
fatigue and appetite loss, and poorer overall QoL summary score in patients with incurable 
cancer. Our findings indicate potential targets for interventions aimed at safeguarding the QoL 
of patients with advanced cancer. Future work should focus on targeting the systemic 
inflammatory response, attenuating WL and improving performance status in patients with 
incurable cancer as a means of improving PROMs and reducing symptom burden. 
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Table 1 Demographic and clinical characteristics of patients included in this study 
 n (%) 
Sex 




   <65, 65-74, >75  
 
483 (47), 300 (29), 244 (2) 
Primary cancer 
   Gastrointestinal 
   Lung 





   Yes 862 (87) 
Performance status (ECOG-PS)a 
   0-1/ 2/ 3/ 4 
 
575 (59), 292 (30), 96 (10), 16 (1) 
mGPSb 
   0, 1, 2 353 (43), 139 (17), 329 (40) 
BMI (kg/m2)c 
<20.0, 20.0-24.9, 25-29.9, >30 
 
122 (13), 348 (37), 299 (31), 180 (19) 
Weight loss (%)d 
<5%, 5-10%, >10% 
 
674 (71), 143 (15), 134 (14) 
Sarcopeniae 192 (45) 
Low muscle attenuationf 223 (54) 
  
Quality of life domains (n=1000) Mean (SD) 
Functioning scales 
   Physical functioning  
   Role functioning 
   Emotional functioning 
   Cognitive functioning 







Cancer-related symptom scales 
   Fatigue 
   Nausea & vomiting 
   Pain 
   Dyspnoea  
   Insomnia 
   Anorexia 
   Constipation 










Global health status 60.6 (24.1) 
Quality of life summary score 73.8 (18.1) 
aECOG available in 979; bmGPS available in 821; cBMI available on 949; d%WL available in 951. 
eCT scans available for muscle mass (sarcopenia) assessment in 428 patients 
fContrast enhanced CT image available for muscle attenuation assessment in 413 patients 
ECOG, The Eastern Oncology Cooperative Group; mGPS, modified Glasgow Prognostic Score; BMI, Body 
Mass Index *Other group consists of Breast, Gynaecological, Genitourinary, Neurological, Haematological, 
Melanoma, Unknown primary and other
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Table 2 Relationship between clinical, nutritional and inflammatory parameters with EORTC-QLQ functional scales.  
ECOG, Eastern Cooperative Oncology Group; mGPS, modified Glasgow Prognostic Score; BMI, Body Mass Index; SMI, Skeletal muscle index; MA, Muscle attenuation.
















Male/female 1027 -.112 0.001 -.028 0.379 -.071 0.024 -.049 0.121 -.035 0.272 .027 0.397 -.080 0.012 
Age (years) 
<65/65-74/>75 1027 -.143 0.001 -.063 0.047 .079 0.012 -.011 0.724 -.054 0.089 -.058 0.065 -.037 0.247 
Metastatic disease 
Yes/No 994 -.013 0.691 -.034 0.286 -.010 0.766 -.031 0.339 -.008 0.797 -.005 0.871 .003 0.927 
ECOG-PS 
0-1/2/3/4 979 -.577 0.001 -.494 0.001 -.255 0.001 -.298 0.001 -.334 0.001 -.410 0.001 -.500 0.001 
mGPS 
0/1/2 821 -.312 0.001 -.272 0.001 -.069 0.051 -.163 0.001 -.158 0.001 -.276 0.001 -.267 0.001 
Weight loss (%) 
<5/5-10/>10 952 -.208 0.001 -.216 0.001 -.111 0.001 -.147 0.001 -.135 0.001 -.207 0.001 -.291 0.001 
BMI (kg/m2) 
<20, 20-24.9, 25-29.9, >30 949  .020 0.545 .086 0.008 .052 0.113 .053 0.106 .085 0.009 .072 0.028 .077 0.018 
Low SMI 
No/Yes 428 
  -.164 0.001 -.070 0.149 -.078 0.103 -.026 0.592 -.104 0.034 -.052 0.282 -.060 0.218 
Low MA 
No/Yes 
413   -.244 0.001   -.145 0.003 
     
.009 
0.857 -.006 0.902 -.072 0.145 -.175 0.001 -.135 0.006 
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Table 3 Relationship between clinical, nutritional and inflammatory parameters with EORTC-QLQ symptom scales.  
Variable n Fatigue 
Nausea & 
Vomiting 




























































Weight loss (%) 






<20, 20-24.9, 25-29.9, >30 
94






















Table 4 Clinical, nutritional and inflammatory parameters related to poor QoL summary 
scores (below the mean <73.8) according to multivariable logistic regression analysis. 
OR, odds ratio; CI, confidence interval; mGPS, modified Glasgow Prognostic Score; BMI, body mass index.  
 
  
  Univariate analysis Multivariate analysis 
























































































































































Weight loss (%) 
<5% 
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 eTable 1. Clinical, nutritional and inflammatory parameters related to poorer physical 
function (below the mean <68.4) according to multivariable logistic regression analysis. 
OR, odds ratio; CI, confidence interval; mGPS, modified Glasgow Prognostic Score; BMI, body mass index.  
 
  
  Univariate analysis Multivariate analysis 








1.52 1.18-1.95 0.001 
1.00 




































































































0.106    
Weight loss (%) 
<5% 


























eTable 2. Clinical, nutritional and inflammatory parameters related to fatigue (above mean 
42.3) according to multivariable logistic regression analysis. 
OR, odds ratio; CI, confidence interval; mGPS, modified Glasgow Prognostic Score; BMI, body mass index.  
  
  Univariate analysis Multivariate analysis 















































































































0.625    
Weight loss (%) 
<5% 


























eTable 3. Clinical, nutritional and inflammatory parameters related to more appetite loss 
(above mean 27.3) according to multivariable logistic regression analysis. 




  Univariate analysis Multivariate analysis 


























































































































Weight loss (%) 
<5% 
  5-10% 
>10% 
 
671 
140 
126 
 
1.00 
3.28 
4.24 
2.20-4.88 
2.83-6.36 
 
<0.001 
<0.001 
 
1.00 
2.38 
2.51 
 
1.51-3.76 
1.58-3.99 
 
<0.001 
<0.001 
